Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach

Area of Science:

• Natural product drug discovery
• Medicinal chemistry
• Tuberculosis research

Background:

• Pyridomycin is a natural product effective against Mycobacterium tuberculosis (Mtb) by inhibiting the InhA enzyme.
• It retains activity against Mtb strains resistant to isoniazid and ethionamide.
• Pyridomycin exhibits poor in vitro metabolic stability, limiting its therapeutic potential.

Purpose of the Study:

• To develop semisynthetic derivatives of pyridomycin with improved metabolic stability and in vitro activity.
• To evaluate the in vivo pharmacokinetic properties and therapeutic efficacy of these derivatives in a murine tuberculosis model.

Main Methods:

• Semisynthesis of pyridomycin derivatives by replacing the hydroxypicolinic acid group with alternative aromatic moieties.
• In vitro assessment of metabolic stability and antibacterial activity against Mtb.
• In vivo pharmacokinetic studies and efficacy evaluation in a murine pulmonary tuberculosis model.

Main Results:

• Several semisynthetic pyridomycin derivatives demonstrated enhanced in vitro metabolic stability and maintained or improved antibacterial activity.
• Despite improved in vitro properties, these derivatives did not show reduced systemic clearance in mice.
• Neither pyridomycin nor its derivatives were effective in the murine pulmonary tuberculosis model.

Conclusions:

• Semisynthesis can yield pyridomycin analogs with enhanced potency and metabolic stability.
• The observed in vitro improvements did not translate to sufficient in vivo efficacy for tuberculosis treatment.
• Further optimization is required to develop pyridomycin-based drugs for tuberculosis therapy.